Nu Skin Enterprises Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Nu Skin Enterprises Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 4.60 $ to 12.80 $ · Last price: 4.60 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Household & Personal Products
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Nu Skin Enterprises Inc NUS | 0.2 | 4.6 | 7.9 | 69.2 | – | -14.3 | -59.8 |
| Procter & Gamble Company PG | 346.0 | 22.1 | 14.9 | 50.9 | 23.1 | 0.3 | -5.3 |
| Colgate-Palmolive Company CL | 70.6 | 35.0 | 19.7 | 60.4 | 20.9 | 1.4 | 9.4 |
| Estee Lauder Companies Inc EL | 34.0 | – | 25.1 | 75.5 | 14.9 | -8.5 | 8.0 |
| Kenvue Inc. KVUE | 33.3 | 21.5 | 13.0 | 58.4 | 21.6 | -2.1 | 3.1 |
| Kimberly-Clark Corporation KMB | 32.6 | 19.3 | 12.0 | 37.6 | 19.7 | -14.2 | -17.5 |
| Church & Dwight Company Inc CHD | 22.5 | 31.9 | 18.7 | 45.6 | 20.2 | 1.6 | 4.7 |
| The Clorox Company CLX | 10.3 | 14.2 | 13.9 | 42.3 | 17.0 | 0.2 | -29.1 |
| ELF Beauty Inc ELF | 5.5 | 213.6 | 28.0 | 71.6 | 1.7 | 24.6 | -36.1 |
| Median of companies shown | 32.6 | 21.8 | 14.9 | 58.4 | 19.9 | 0.2 | -5.3 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2,208 | 231 | 143 | 2.55 | 275 | 664 | 1,474 |
| 2017 | 2,279 | 274 | 129 | 2.36 | 303 | 705 | 1,590 |
| 2018 | 2,679 | 241 | 122 | 2.16 | 203 | 782 | 1,694 |
| 2019 | 2,420 | 267 | 174 | 3.10 | 178 | 875 | 1,769 |
| 2020 | 2,582 | 258 | 191 | 3.63 | 379 | 894 | 1,957 |
| 2021 | 2,696 | 234 | 147 | 2.86 | 142 | 913 | 1,906 |
| 2022 | 2,226 | 111 | 105 | 2.07 | 108 | 897 | 1,821 |
| 2023 | 1,969 | 48 | 9 | 0.17 | 119 | 822 | 1,806 |
| 2024 | 1,732 | -152 | -147 | -2.95 | 112 | 651 | 1,469 |
| 2025 | 1,485 | 91 | 160 | 3.18 | 80 | 805 | 1,405 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.73 | -593.50 | 446 | -8.80 | -8.10 | 26 | 13 |
| 2025: Q1 | 2.14 | – | 365 | -12.70 | 29.50 | 0 | -13 |
| 2025: Q2 | 0.43 | – | 386 | -12.10 | 5.50 | 36 | 36 |
| 2025: Q3 | 0.34 | 103.40 | 364 | -15.30 | 4.70 | 28 | 18 |
| 2025: Q4 | 0.29 | – | 370 | -16.90 | 3.90 | 17 | 6 |
| 2026: Q1 | 0.04 | -98.30 | 321 | -12.00 | 0.60 | -4 | -18 |
| 2026: Q2 | -5.14 | -1,295.30 | 320 | -17.10 | -78.00 | 11 | 5 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Momentum & Trend
Risk & Weakness
- Below the 50- & 200-SMA
- Near 52-Week Low
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Value & GARP
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.82 | 0.82 – 0.82 | 1,317 | -35.4% | 1 |
| 12/31/2027 | 1.16 | 1.16 – 1.16 | 1,474 | 41.5% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 7.5% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $10.8M |
|---|---|
| Market cap | $213.0M |
| Free cash flow in year ten | $22.3M |
| Terminal value as a share of market value | 55.2% |
For comparison: over the past five years free cash flow shrank by 32.0% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -12.6%
- More than 10% revenue growth is expected for the coming year 7.3%
- Share count grows by less than 3% a year -0.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -11.2%
- Gross margin at 40% or higher and without meaningful erosion 69.5%
- Goodwill from acquisitions does not grow faster than revenue 6.0%
- Net debt below twice EBITDA 0.5 x EBITDA
- Operating cash flow covers the profits of the last three years 288 m
- Return on capital at 15% or higher, or up versus two years ago 8.0%
- Insiders hold at least 10% or are net buyers 3.4%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -4.3%
- Exp. sales growth 3Y > 5% -0.4%
- EBIT growth 10Y > 5% -9.9%
- Exp. EBIT growth 3Y > 5% -39.6%
- Net debt < 4x EBIT 1.4x
- EBIT positive, 10Y straight 9
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% 23.6%
- ROCE > 15% 8.0%
- Expected return > 10% -26.6%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Woodbury Edwina D | Director | Other | 22 | 4.85 | 107 |
The company
About the Company
Nu Skin Enterprises, Inc. entwickelt und vertreibt zusammen mit seinen Tochtergesellschaften weltweit verschiedene Beauty- und Wellnessprodukte.
- Employees
- 2,800
- Headquarters
- Provo, UT
- Address
- 75 West Center Street, 84601 Provo, United States
- Phone
- 801 345 1000
- Website
- nuskin.com
- IPO Date
- 11/21/1996
- ISIN
- US67018T1051
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven J. Lund J.D. | Co-Founder & Executive Chairman of the Board | 1953 |
| Ryan S. Napierski | President, CEO & Director | 1974 |
| Chayce David Clark | Executive VP, COO & Chief Legal Officer | 1983 |
| Justin S. Keisel | Executive VP & President of Global Sales (Leave of Absence) | 1974 |
| Blake M. Roney | Founder | 1959 |
| Sandra N. Tillotson | Founder | 1957 |
| Chelsea Lantz | Chief Financial Officer | 1984 |
| Joe Sueper | Senior VP & CTO | – |
| Joseph Y. Chang Ph.D. | Executive VP, Chief Scientific Officer & Chair of Scientific Advisory Board | 1953 |
| B.G. Hunt | VP of Treasurer, Investor Relations & Admin Services | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/21/2026 NU SKIN ENTERPRISES, INC. (NUS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers SEC ↗
- 08/10/2026 NU SKIN ENTERPRISES, INC. (NUS): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.